In summary, our results indicate that Epag is a clinically relevant DNA dioxygenase inhibitor and this activity may contribute, in addition to its TPOR agonistic effect, to its efficacy in aplastic anemia, including reexpansion of HSPCs. Here, MPL is linked to idiopathic aplastic anemia.